Press release
Age-Related Macular Degeneration Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight
Explore the intricate details of the Age-related Macular Degeneration Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Age-related Macular Degeneration Market Forecast. Click here to stay ahead in healthcare innovation @ Age-related Macular Degeneration Market Size [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Age-related Macular Degeneration Market Report
* In November 2024:- Genentech Inc.- The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells. The study will also include initial exploration of the ability of transplanted OpRegen cells to engraft, survive, and moderate disease progression.
* In November 2024:- Stealth Bio Therapeutics Inc.- The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.
* In November 2024:- 4D Molecular Therapeutics- A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults with Neovascular (Wet) Age-Related Macular Degeneration. This Phase 1/2 trial is a prospective, multicenter, Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment who have demonstrated a clinical response consistent with anti-VEGF activity. The trial consists of Dose Escalation, Dose Expansion, Steroid Optimization and Population Extension Cohorts.
* In the year 2022, the total prevalent cases of AMD were approximately 52,684,880 in the 7MM, which might increase at a decent CAGR by 2034.
* The US accounted for approximately 17,688,550 prevalent cases of AMD in the year 2022.
* The leading Age-related Macular Degeneration Companies such as Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics , and others.
* Promising Age-related Macular Degeneration Therapies such as NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101 , and others.
Delve deep into the Age-related Macular Degeneration Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Age-related Macular Degeneration Market Forecast. Click here to shape the future @ Age-related Macular Degeneration Epidemiology Insights [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Age-related Macular Degeneration Epidemiology Insights
* Total Age-related Macular Degeneration Prevalent Cases
* Total Age-related Macular Degeneration Age-specific Cases
* Total Age-related Macular Degeneration Diagnosed Prevalent Cases
* Total Age-related Macular Degeneration Diagnosed Dry AMD Cases by stages
* Total Age-related Macular Degeneration Geographic Atrophy Cases by Visual Impairment
* Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases
Navigate the complexities of the Age-related Macular Degeneration Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Age-related Macular Degeneration Market Forecast. Click here to get more insights @ Age-related Macular Degeneration Prevalence [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Age-related Macular Degeneration Market Insights
Age-related Macular Degeneration is the most common cause of severe loss of eyesight among people aged 50 and older. It affects the central vision and, with it, the ability to see fine details. In AMD, a part of the retina called the macula get damaged. Medication can help reduce the progression of the illness and prevent vision loss.
Age-related Macular Degeneration Treatment Landscape
The best available treatment for AMD was photodynamic therapy-in which an intravenous drug (injected into a vein) and laser were used to seal off leaking blood vessels. Past studies have found that just 1 year after diagnosis, less than 15% of patients given this therapy alone retain 20/40 vision, and up to 40% decline to 20/200 vision. However, advances in medical research have identified the Vascular Endothelial Growth Factor (VEGF) as a key pathophysiological factor in the development of neovascular AMD, with an essential role in angiogenesis, vascular permeability, and inflammatory response. The introduction of anti-VEGF intravitreal injections has opened a new therapeutic window in the management of wet AMD, thus efficiently blocking the pathophysiological process of AMD, with a restoration of retinal morphology and the maintenance of its function.
Age-related Macular Degeneration Market Size
According to the DelveInsight analysis, the United States accounted for the highest market size, with approximately 50% of the market share of Dry age-related Macular Degeneration (AMD) as compared to other countries of the 7MM in the year 2022. The Age-related Macular Degeneration market size of the 7MM is anticipated to increase in the forecast period due to expected launch of emerging therapies in the 7MM.
Unlock insights into the Age-related Macular Degeneration Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Age-related Macular Degeneration Market Forecast. Click here @ Age-related Macular Degeneration Market Drivers and Barriers [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Age-related Macular Degeneration Therapies and Companies
* Eylea (aflibercept): Regeneron Pharmaceuticals
* Beovu(brolucizumab): Novartis
* Lucentis (ranibizumab): Roche
* Vabysmo (faricimab): Roche
* Susvimo (ranibizumab): Roche
Age-related Macular Degeneration Drug Market
The overall Age-related Macular Degeneration (AMD) Market is expected to boost due to rising prevalence cases over the globe and thus the surge in treatment options. Along with the expected launch of emerging therapies, the treatment market of Wet-AMD and Dry-AMD is supposed to boost in the forecasted period (2024-2034).
Scope of the Age-related Macular Degeneration Market Report
* Coverage- 7MM
* Age-related Macular Degeneration Companies- Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others.
* Age-related Macular Degeneration Therapies- NG101 AAV gene therapy, Iptacopan (LNP023), VOY-101, and others.
* Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration Market drivers and Age-related Macular Degeneration Market Barriers
* Age-related Macular Degeneration Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
* Age-related Macular Degeneration Unmet Needs, KOL's views, Analyst's views, Age-related Macular Degeneration Market Access and Reimbursement
Gain a strategic edge in the Age-related Macular Degeneration Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Age-related Macular Degeneration Market Forecast. Click here to lead in advancements @ Age-related Macular Degeneration Clinical Trials Assessment [https://www.delveinsight.com/sample-request/age-related-macular-degeneration-amd-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
1. Key Insights
2. Report Introduction
3. Wet AMD Market Overview at a Glance
4. Dry AMD Market Overview at a Glance
5. Wet AMD Market: Future Perspective
6. Executive Summary
7. Key Events
8. Disease Background and Overview
9. Epidemiology and Patient Population
10. Patient Journey
11. Marketed Drugs
12. Emerging Drugs of Wet AMD
13. Emerging Drugs of Dry AMD
14. AMD: Seven Major Market Analysis
15. Key Opinion Leaders' Views
16. Market Drivers
17. Market Barriers
18. SWOT Analysis
19. Market Access and Reimbursement of Wet AMD
20. Unmet Needs
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=agerelated-macular-degeneration-market-size-in-the-7mm-is-expected-to-grow-by-2034-estimates-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Age-Related Macular Degeneration Market Size in the 7MM is expected to Grow by 2034, estimates DelveInsight here
News-ID: 3722113 • Views: …
More Releases from ABNewswire
Uplers Highlights 2025 Trend: Brands Compete to Hire Graphic Designers With Adva …
The design industry is entering a new era in 2025 and the years to come. Creativity and artificial intelligence are merging to reshape how visual content is being produced. For brands, this no longer is a trend to monitor, instead it's a race to secure the right and skilled talent. Companies are fiercely competing to hire graphic designers who can harness AI tools to deliver innovation, speed, and consistency across…
Inside Uplers Latest Report: What Companies Should Know About Angular Developer …
Angular continues to be one of the widely adopted front-end frameworks for dynamic and scalable app development. With digital products becoming increasingly complex, global hiring managers are continuing to face the challenge of finding Angular talent for balancing cost and availability.
In response to this, Uplers is publishing new salary insights based on the evolving hiring trends for supporting companies in shaping their competitive strategies to hire Angular developers [https://www.uplers.com/hire-angularjs-developers/]. The…
The Moss Way: Unlocking the True Power of Irish Sea Moss for Modern Wellness
London, United Kingdom - 7 Oct, 2025 - As the wellness industry evolves, a growing number of people are turning back to nature's timeless remedies - and few are as powerful or as misunderstood as Irish Sea Moss. Leading this natural health renaissance is The Moss Way, a UK-based wellness brand redefining what it means to nourish the body with pure, sustainably sourced superfoods. With a focus on authenticity, science,…
New Outdoor Retailer Feeling My Adventure Empowers Digital Detox Through Compreh …
The outdoor retail sector welcomes Feeling My Adventure, a new e-commerce venture operated by Ingrid K Santana Ramirez LLC, offering comprehensive equipment solutions for camping, survival preparedness, and outdoor recreation activities. Launching at feelingmyadventure.com, the platform distinguishes itself through a philosophy emphasizing nature's role in personal restoration and the importance of disconnecting from digital saturation to rediscover authentic human experiences.
Market timing for the launch aligns with growing societal recognition of…
More Releases for Macular
2025-2034 Macular Edema and Macular Degeneration Market Roadmap: Insights for Co …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
How Large Will the Macular Edema and Macular Degeneration Market Size By 2025?
In the past few years, the market size for macular edema and macular degeneration has seen significant growth. It is projected to increase from $9.65 billion in 2024 to $10.43 billion in 2025, exhibiting a compound…
Macular Edema and Macular Degeneration Market Outlook 2025-2034: Key Trends, Gro …
"How Big Is the Macular Edema and Macular Degeneration Market Expected to Be, and What Will Its Growth Rate Be?
The macular edema and macular degeneration market has seen significant growth in recent years. It will expand from $9.65 billion in 2024 to $10.43 billion in 2025, with a CAGR of 8.1%. Factors contributing to this growth include the aging population, increasing diabetes prevalence, early diagnosis and awareness, global initiatives in…
Macular Edema and Macular Degeneration Market to Reach $22.51 Billion by 2034
The global macular edema and macular degeneration market, valued at $10.33 billion in 2023, is on track to grow at a remarkable compound annual growth rate (CAGR) of 7.34%, reaching $22.51 billion by 2034. This substantial market expansion is being fueled by rising treatment innovations, an increasing global prevalence of related diseases, and a surge in technological advancements in diagnostics and therapies.
Download White Paper: https://www.towardshealthcare.com/download-statistics/5375
Market Overview and Key Drivers
The macular…
Macular Edema and Macular Degeneration Market Size, Trends, Growth, Outlook 2024 …
"The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.
Macular Edema and Macular Degeneration Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.
The Market Size Is Expected To Reach $12.84…
Macular Edema and Macular Degeneration Market: Key Trends, Competitor Analysis, …
"Exploring the Global Macular Edema and Macular Degeneration Market: A Comprehensive Overview
Insights into Macular Edema and Macular Degeneration Market: Global Trends and Analysis
Macular Edema and Macular Degeneration Industry - Key Market Dynamics and Trends
The macular edema and macular degeneration market size has grown strongly in recent years. It will grow from $8.84 billion in 2023 to $9.65 billion in 2024 at a compound annual growth rate (CAGR) of 9.1%. The…
Global Macular Edema and Macular Degeneration Why This Topic is So Serious Nowad …
According to the report published by Allied Market Research, the Global Macular Edema And Macular Degeneration Market generated $8.30 billion in 2020, and is expected to reach $16.53 billion by 2030, exhibiting a CAGR of 7.3% from 2021 to 2030. The report offers an in-depth analysis of the market size, emerging and current trends, future estimations, and key players.
♦ 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐅𝐫𝐞𝐞 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐑𝐞𝐩𝐨𝐫𝐭:
https://www.alliedmarketresearch.com/request-sample/620
𝗖𝗢𝗩𝗜𝗗-𝟭𝟵 𝗜𝗺𝗽𝗮𝗰𝘁 𝗔𝗻𝗮𝗹𝘆𝘀𝗶𝘀 (𝗣𝗿𝗲 & 𝗣𝗼𝘀𝘁)…
